{"id":"https://openalex.org/W772862339","doi":"https://doi.org/10.1212/wnl.84.14_supplement.p6.044","title":"Decreased burden among caregivers of patients with Parkinson\u2019s disease psychosis (PDP) treated with pimavanserin, a selective 5-HT2A inverse agonist (P6.044)","display_name":"Decreased burden among caregivers of patients with Parkinson\u2019s disease psychosis (PDP) treated with pimavanserin, a selective 5-HT2A inverse agonist (P6.044)","publication_year":2015,"publication_date":"2015-04-06","ids":{"openalex":"https://openalex.org/W772862339","doi":"https://doi.org/10.1212/wnl.84.14_supplement.p6.044","mag":"772862339"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.84.14_supplement.p6.044","doi":"https://doi.org/10.1212/wnl.84.14_supplement.p6.044","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.84.14_supplement.p6.044","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5051934606","display_name":"Dag Aarsland","orcid":"https://orcid.org/0000-0001-6314-216X","observed_orcids":["https://orcid.org/0000-0001-6314-216X"]},"institutions":[{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Dag Aarsland","raw_affiliation_strings":["Department of Neurobiology, Care Sciences & Society (NVS), Division of Alzheimer's Disease Research Karolinska Instituet Stockholm Sweden","Rogaland Psychiatric Hospital Stavanger Norway"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurobiology, Care Sciences & Society (NVS), Division of Alzheimer's Disease Research Karolinska Instituet Stockholm Sweden","institution_ids":["https://openalex.org/I28166907"]},{"raw_affiliation_string":"Rogaland Psychiatric Hospital Stavanger Norway","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003930471","display_name":"Roger Mills","orcid":"https://orcid.org/0000-0002-3993-4180","observed_orcids":["https://orcid.org/0000-0002-3993-4180"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Roger Mills","raw_affiliation_strings":["San Diego CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"San Diego CA United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104349049","display_name":"Hilde Williams","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hilde Williams","raw_affiliation_strings":["San Diego CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"San Diego CA United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044950719","display_name":"Kathy Chi\u2010Burris","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I125377440","display_name":"Acadia Pharmaceuticals (United States)","ror":"https://ror.org/030bhbq32","country_code":"US","type":"company","lineage":["https://openalex.org/I125377440"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kathy Chi-Burris","raw_affiliation_strings":["ACADIA Pharmaceuticals San Diego CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ACADIA Pharmaceuticals San Diego CA United States","institution_ids":["https://openalex.org/I125377440"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051566796","display_name":"Michaela Karistedt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I75511499","display_name":"Marie Cederschi\u00f6ld University","ror":"https://ror.org/00ajvsd91","country_code":"SE","type":"education","lineage":["https://openalex.org/I75511499"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Michaela Karistedt","raw_affiliation_strings":["Department of Health Care Services Ersta Skondal University College Stockholm Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Health Care Services Ersta Skondal University College Stockholm Sweden","institution_ids":["https://openalex.org/I75511499"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032708452","display_name":"Clive G. Ballard","orcid":"https://orcid.org/0000-0003-0022-5632","observed_orcids":["https://orcid.org/0000-0003-0022-5632"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Clive Ballard","raw_affiliation_strings":["Newcastle General Hospital Newcastle United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Newcastle General Hospital Newcastle United Kingdom","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.01451195,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"84","issue":"14_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9218999743461609,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9218999743461609,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12980","display_name":"Family Caregiving in Mental Illness","score":0.027799999341368675,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T13111","display_name":"Nursing care and research","score":0.011099999770522118,"subfield":{"id":"https://openalex.org/subfields/2922","display_name":"Research and Theory"},"field":{"id":"https://openalex.org/fields/29","display_name":"Nursing"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pimavanserin","display_name":"pimavanserin","score":0.8889999985694885},{"id":"https://openalex.org/keywords/parkinson-s-disease-psychosis","display_name":"Parkinson's disease psychosis","score":0.9980000257492065},{"id":"https://openalex.org/keywords/caregiver-burden","display_name":"caregiver burden","score":0.984000027179718},{"id":"https://openalex.org/keywords/zarit-burden-interview","display_name":"Zarit Burden Interview","score":0.7450000047683716},{"id":"https://openalex.org/keywords/antipsychotic-drugs","display_name":"antipsychotic drugs","score":0.7450000047683716},{"id":"https://openalex.org/keywords/sleep-and-wakefulness","display_name":"sleep and wakefulness","score":0.6190000176429749},{"id":"https://openalex.org/keywords/benefit-risk-profile","display_name":"benefit-risk profile","score":0.6370000243186951}],"concepts":[{"id":"https://openalex.org/C2779727114","wikidata":"https://www.wikidata.org/wiki/Q170082","display_name":"Psychosis","level":2,"score":0.8178210258483887},{"id":"https://openalex.org/C2779734285","wikidata":"https://www.wikidata.org/wiki/Q11085","display_name":"Parkinson's disease","level":3,"score":0.6611385345458984},{"id":"https://openalex.org/C89951826","wikidata":"https://www.wikidata.org/wiki/Q1671731","display_name":"Inverse agonist","level":4,"score":0.6606018543243408},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6140351295471191},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5983220338821411},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.4470418095588684},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.43784862756729126},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.24236562848091125},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.09326866269111633}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.84.14_supplement.p6.044","doi":"https://doi.org/10.1212/wnl.84.14_supplement.p6.044","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.84.14_supplement.p6.044","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2072408136","https://openalex.org/W1965174391","https://openalex.org/W2333444689","https://openalex.org/W2056703646","https://openalex.org/W4389460210","https://openalex.org/W3181433083","https://openalex.org/W4389447114","https://openalex.org/W6980681353","https://openalex.org/W4365511282","https://openalex.org/W2809076718"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"determine":[2],"the":[3,99,112,145,171,221,248],"effect":[4,141],"of":[5,111,121,198,251],"pimavanserin,":[6],"a":[7,38,81,266],"selective":[8,253],"5-HT2A":[9,40,254],"inverse-agonist,":[10],"on":[11,236,261],"caregiver":[12,29,88,102,207,237],"burden.":[13],"BACKGROUND:":[14],"Parkinson's":[15],"Disease":[16],"Psychosis":[17],"(PDP)":[18],"is":[19,37],"associated":[20],"with":[21,190,213,242],"functional":[22],"and":[23,27,66,94,97,158,216,263,265],"cognitive":[24],"decline,":[25],"morbidity/mortality,":[26],"increased":[28],"burden":[30,103,167,238],"often":[31],"leading":[32],"to":[33,90,232],"early":[34],"institutionalization.":[35],"Pimavanserin":[36,58],"potent":[39],"inverse-agonist":[41,255],"being":[42],"developed":[43],"for":[44,155,160,170,211,230],"PDP.":[45,75],"Unlike":[46],"current":[47],"antipsychotics,":[48],"it":[49],"has":[50,257],"no":[51],"dopaminergic,":[52],"histaminergic,":[53],"adrenergic":[54],"or":[55,131,137,192],"muscarinic":[56],"activity.":[57],"40mg":[59,130,162],"demonstrated":[60],"improvements":[61],"in":[62,69,74,125,144,166],"psychosis,":[63],"nighttime":[64],"sleep":[65,193,264],"daytime":[67],"wakefulness":[68],"randomized":[70],"controlled":[71],"trials":[72],"(RCTs)":[73],"RCT":[76,93],"completers":[77],"could":[78],"roll":[79],"into":[80],"long-term":[82],"open-label":[83],"study":[84,204],"(OLS).":[85],"A":[86],"consented":[87],"had":[89],"attend":[91],"all":[92],"OLS":[95],"visits":[96],"complete":[98],"Zarit":[100],"22-item":[101],"scale":[104],"(CBS).":[105],"METHOD:":[106],"In":[107,220],"an":[108],"integrated":[109],"analysis":[110],"6-week":[113],"RCTs,":[114],"CBS":[115,151,223],"scores":[116,152,224],"were":[117,135,153],"evaluated":[118],"among":[119,239],"caregivers":[120,134],"268":[122],"PDP":[123],"patients":[124,212],"N.America":[126],"who":[127],"received":[128],"pimavanserin":[129,161,172,199],"placebo.":[132],"Most":[133],"spouses":[136],"other":[138,203],"family.":[139],"Continued":[140],"was":[142,168,209],"assessed":[143],"OLS.":[146],"RESULTS:":[147],"Mean":[148],"baseline":[149],"(pretreatment)":[150],"30.6":[154],"placebo":[156,177],"(N=133)":[157],"28.8":[159],"(N=135).":[163],"Significant":[164],"improvement":[165],"observed":[169,210],"group":[173],"(-4.8":[174],"points)":[175,179],"over":[176],"(-1.1":[178],"at":[180],"6":[181],"weeks":[182],"(p=0.0009).":[183],"These":[184],"results":[185],"did":[186],"not":[187,200],"strongly":[188],"correlate":[189],"psychosis":[191,262],"improvements,":[194],"suggesting":[195],"broader":[196],"benefits":[197],"captured":[201],"by":[202],"measures.":[205],"More":[206],"benefit":[208,260],"less":[214,217],"dementia":[215],"co-morbid":[218],"disease.":[219],"OLS,":[222],"remained":[225],"generally":[226],"stable":[227],"(+1-point":[228],"difference)":[229],"up":[231],"9":[233],"months.CONCLUSIONS:":[234],"Improvements":[235],"pimavanserin-treated":[240],"people":[241],"PDP,":[243],"provide":[244],"important":[245],"context":[246],"around":[247],"benefit-risk":[249],"profile":[250],"this":[252],"that":[256],"shown":[258],"significant":[259],"well-tolerated":[267],"safety":[268],"profile.":[269]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}